BridgeBio Pharma Asset Turnover 2018-2023 | BBIO
Current and historical asset turnover for BridgeBio Pharma (BBIO) from 2018 to 2023. Asset turnover can be defined as the amount of sales or revenues generated per dollar of assets. The asset turnover ratio is an indicator of the efficiency with which a company is deploying its assets. BridgeBio Pharma asset turnover for the three months ending December 31, 2023 was 0.00.
| BridgeBio Pharma Asset Turnover Historical Data |
| Date |
|
|
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$5.208B |
$0.009B |
|
BridgeBio Pharma Inc. discovers, develops and innovates drugs for genetic diseases. The Company's product platform consists of Mendelian, Oncology and Gene therapy. Its product pipeline includes BBP-265, BBP-831, BBP-631 and BBP-454 which are in clinical stage. BridgeBio Pharma Inc. is based in CA, United States.
|
